论文部分内容阅读
为了观察中西药物乙型肝炎疫苗、聚肌胞、猪苓多糖及解瘀通络肝炎口服液联合应用对慢性乙型肝炎的疗效。治疗组 48例使用乙型肝炎疫苗、聚肌胞、猪苓多糖及中药解瘀通络肝炎口服液和一般保肝药物 ,对照组 30例仅使用一般性保肝药物 ,共 3个月为 1个疗程。结果治疗组HBsAg、HBeAg和HBVDNA的阴转率分别为 8.33% ,75 %和 79.2 % ,与对照组比较 ,后二者具有明显性差异。治疗组HBsAb和HBeAb阳转率分别为 2 0 .8%和 43.8% ,与对照组比较均具有显著差异。说明中西药物乙型肝炎疫苗、聚肌胞、猪苓多糖及解瘀通络肝炎口服液联合使用治疗慢性乙型肝炎疗效较好 ,且副作用小。
In order to observe the curative effect of combination therapy of hepatitis B vaccine, polymyosine, polyporus polysaccharide and Jieyu Tongluo Hepatitis oral solution of Chinese and western medicine on chronic hepatitis B. The treatment group of 48 patients with hepatitis B vaccine, polymyosin, Polyporus umbellatus and Chinese medicine Jieyu Tongluo Hepatitis oral liquid and general liver protection drugs, the control group of 30 patients with only general liver protection drugs, a total of 3 months to 1 A course of treatment. Results The negative conversion rates of HBsAg, HBeAg and HBVDNA in the treatment group were 8.33%, 75% and 79.2%, respectively, which were significantly different from those in the control group. The positive rates of HBsAb and HBeAb in the treatment group were 20.8% and 43.8% respectively, which were significantly different from those in the control group. This shows that the combination of Chinese medicine and western medicine Hepatitis B vaccine, polymyositis, Polyporus umbellatus polysaccharide and Jieyu Tongluo Hepitherapy oral liquid have better curative effect and less side effects.